Effect of teneligliptin 20 mg twice daily on glucagon like-peptide-1 (GLP-1) levels and its influence on non-glycemic components in non-diabetic obese individuals

Abstract

Abstract Background and aims: Teneligliptin is an oral anti-diabetic agent, it can persevere GLP-1 by inhibiting DPP-4 enzyme. Also had rare incidence of hypoglycemia. Hence, the present study was aimed to test the effect of teneligliptin 20 mg twice daily along with low carbohydrate diet and physical exercise on change of body weight, insulin resistance in non-diabetic obese subjects. Methods: It is a prospective, randomized, placebo controlled, parallel group study carried out at outpatient department of an endocrinology hospital over the period of 48 weeks. Teneligliptin 20 mg twice daily 30 min before food (Low carbohydrate diet) with regular physical exercise and control group was kept with only LCD diet and regular physical exercise. The present Study was registered in clinical trial registry of India [CTRI/2020/02/023329]. Results: A total of 150 non diabetic obese subjects were randomized into test (n=75) and control group (n=75). At the end of the 48th weeks significant improvement of GLP-1, SNAQ score, HOMA-IR, Triglycerides, and body weight. The mean difference and 95% CI of GLP-1 (pg/mL) was 76.42 (44.42, 148.41) (p 0.37); SNAQ score, -1.64 (-2.48, -0.81) (p 0.000); HOMA-IR, -0.9 (-0.59, -0.38) (p 0.000); Triglycerides (mg/dL) - 29.37 (-44.46, -14.07) (p 0.000); reduction of body weight (kg) -3.09 (-6.11, -0.07) (p 0.043). Conclusion: Findings of this study reveals that teneligliptin treated group showed significant improvement of GLP-1 levels, reduced insulin resistance, body weight, triglycerides, appetite, and metabolic syndrome. Teneligliptin is well tolerated, except upper respiratory tract infections.